Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. While the causes of AD are not known, several risk factors have been identified. Among these, type 2 diabetes (T2D), a chronic metabolic disease, is one of the most prevalent risk factors for AD. Insulin resistance, which is associated with T2D, is defined as diminished or absent insulin signaling, and is reflected by peripheral blood hyperglycemia and impaired glucose clearance. In this study, we used complimentary approaches to probe for peripheral insulin resistance, central nervous system (CNS) insulin sensitivity and energy homeostasis in Tg2576 and 3xTg-AD mice, two widely used animal models of AD. We report that CNS insulin signaling abnormalities are evident months before peripheral insulin resistance. Additionally, we find that brain energy metabolism is differentially altered in both mouse models, with the 3xTg-AD mice showing more extensive changes. Collectively, our data suggest that early AD may reflect engagement of different signaling networks that influence CNS metabolism, which in-turn may alter peripheral insulin signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 2×
“Peripheral insulin resistance is often associated with increased body weight and obesity (Kahn et al., 2006).”
BackgroundResult2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 10×
“The insulin receptor (IR), the insulin receptor substrate-1 (IRS-1), the phosphoinositide-dependent kinase-1 (PDK1), and the alpha serine/threonineprotein kinase (AKT) are regulated through stoichiometric activation/inactivation phosphorylation profiles and form the components of a highly integrated intracellular insu…”
BackgroundResultInfluentialSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 5×
“The insulin receptor (IR), the insulin receptor substrate-1 (IRS-1), the phosphoinositide-dependent kinase-1 (PDK1), and the alpha serine/threonineprotein kinase (AKT) are regulated through stoichiometric activation/inactivation phosphorylation profiles and form the components of a highly integrated intracellular insu…”
BackgroundInfluentialHawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., & Hardie, D. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27879 · Cited by 1,264
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 6×
“Given that the 3xTg-AD mice develop NFTs, this suggests that AMPK upregulation may contribute to or even be a consequence of the tau pathology unique to this model (Oddo et al., 2003).”
BackgroundMethodInfluentialSelf-citationIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“Epidemiological, clinical, and preclinical, evidence compellingly suggests that T2D and AD bear interrelated disease risks and mechanisms (Haan, 2006; Heneka et al., 2015; Janson et al., 2004; Kandimalla et al., 2016; Steen et al., 2005).”
BackgroundPositive and negative regulation of insulin signaling through IRS-1 phosphorylation
Gual, P., Le Marchand-Brustel, Y., & Tanti, J.-F. (2005) · Biochimie · doi:10.1016/j.biochi.2004.10.019 · Cited by 912 · cited 8×
“The insulin receptor (IR), the insulin receptor substrate-1 (IRS-1), the phosphoinositide-dependent kinase-1 (PDK1), and the alpha serine/threonineprotein kinase (AKT) are regulated through stoichiometric activation/inactivation phosphorylation profiles and form the components of a highly integrated intracellular insu…”
BackgroundInfluentialAMPK signalling in health and disease
Carling, D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.01.005 · Cited by 797 · cited 1×
“Energy homeostasis is an additional dimension to the cellular and physiological dysfunction related to insulin resistance and T2D (Carling, 2017; Porte, 2006; Saha et al., 2010).”
BackgroundInsulin signaling in health and disease
White, M. F. (2003) · Science · doi:10.1126/science.1092952 · Cited by 733 · cited 1×
“…of the PDK1/AKT pathways, induces glycogen synthesis through the target of rapamycin complexes to control AMP-activated protein kinase (AMPK), energy metabolism, mitochondrial function, synaptic plasticity and memory (Cheng et al., 2010; Kleinridders et al., 2014; Stoica et al., 2011; White, 2003).”
BackgroundIs Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Phosphorylation of IRS proteins, insulin action, and insulin resistance
Boura-Halfon, S., & Zick, Y. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90437.2008 · Cited by 598
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · cited 2×
“) contribute to the prevalence of AD (Alzheimer’s Association, 2016; Grober et al., 2008; Head et al., 2016; Kivipelto et al., 2002; Moll et al., 2014; Wiseman et al., 2015).”
BackgroundDineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462 · cited 2×
“2.3 Immunoblot Immunoblots were performed on Tg2576 and 3xTg-AD brain homogenates using our previously described methods (Caccamo et al., 2015; Denner et al., 2012; Dineley et al., 2001; Sando et al., 2011; Velazquez et al., 2016).”
BackgroundMethodInfluentialSelf-citationGriffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459 · cited 1×
“Alteration of AKT signaling has emerged as an important feature of neurodegenerative diseases characterized by neuronal attrition, which includes AD (Griffin et al., 2005).”
BackgroundTanti, J.-F., & Jager, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.07.004 · Cited by 430
Reversible memory loss in a mouse transgenic model of Alzheimer’s disease
Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., & Ashe, K. H. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06331.2002 · Cited by 420 · cited 2×
“AMPK is dysregulated concomitant with central insulin resistance in 10-month-old 3xTg-AD mice yet occurs much later in 13-month-old Tg2576 mice and is associated with further decline in Tg2576 mice cognitive function (Ashe, 2006; Cacucci et al., 2008; Dineley et al., 2001; Kotilinek et al., 2002; Saha et al., 2010; We…”
BackgroundMairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., & Polleux, F. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.003 · Cited by 351
Cao, D., Lu, H., Lewis, T. L., & Li, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703561200 · Cited by 336 · cited 2×
“The link between insulin resistance and AD is further strengthened by data showing that diet-induced insulin resistance exacerbates Aβ accumulation, tau phosphorylation and cognitive impairments, and leads to the development of a diabetes-like phenotype (Cao et al., 2007; Carvalho et al., 2012; Orr et al., 2014).”
BackgroundModulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307 · cited 2×
“In the CNS, insulin impinges upon its receptor to activate insulin signaling and the expression of genes that modulate memory (Dineley et al., 2014; Watson and Craft, 2004).”
BackgroundAging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289 · cited 2×
“) contribute to the prevalence of AD (Alzheimer’s Association, 2016; Grober et al., 2008; Head et al., 2016; Kivipelto et al., 2002; Moll et al., 2014; Wiseman et al., 2015).”
BackgroundTherapy insight, type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease
Haan, M. N. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0124 · Cited by 284 · cited 2×
“Compelling evidence suggests that insulin resistance and T2D worsen AD pathology and cognitive deficits (Haan, 2006; Ramos-Rodriguez et al., 2016; Saedi et al., 2016; Sena et al., 2015; Sheen and Sheu, 2016; Zilliox et al., 2016).”
BackgroundBosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265
Stoica, L., Zhu, P. J., Huang, W., Zhou, H., Kozma, S. C., & Costa-Mattioli, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014715108 · Cited by 232 · cited 4×
“…of the PDK1/AKT pathways, induces glycogen synthesis through the target of rapamycin complexes to control AMP-activated protein kinase (AMPK), energy metabolism, mitochondrial function, synaptic plasticity and memory (Cheng et al., 2010; Kleinridders et al., 2014; Stoica et al., 2011; White, 2003).”
BackgroundInfluentialPEDERSEN, W., & FLYNN, E. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.003 · Cited by 108 · cited 2×
“These changes are accompanied by peripheral insulin resistance by 9 months of age (as measured by the GTT), which coincides with the onset of Aβ accumulation in the brain (Hsiao et al., 1996; Pedersen and Flynn, 2004; Rodriguez-Rivera et al., 2011).”
Background
Cited by
Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Van Giau, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 393
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Brain insulin resistance, which can be induced by systemic insulin resistance [19-23] or independently by brain Aβ oligomers and hyperphosphorylated tau [24], promotes many AD-like [22, 25-27] and PD-like [16, 28, 29] pathologies.”
BackgroundVelazquez, R., Ferreira, E., Knowles, S., Fux, C., Rodin, A., Winslow, W., & Oddo, S. (2019) · Aging Cell · doi:10.1111/acel.13037 · Cited by 156
Self-citationCognitive dysfunction: a growing link between diabetes and Alzheimer’s disease
Jash, K., Gondaliya, P., Kirave, P., Kulkarni, B., Sunkaria, A., & Kalia, K. (2020) · Drug Development Research · doi:10.1002/ddr.21579 · Cited by 119
Rhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
Metadata
- Authors
- Velazquez, R., Tran, A., Ishimwe, E., Denner, L., Dave, N., Oddo, S., & Dineley, K. T.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 58
- Pages
- 1-13
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2651360079
- Cited by
- 90
- References
- 27
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.